Table 1.
Baseline Characteristics of benign and EOC patients.
| Characteristics (N=129) |
iCTCs≤5Δ
54 (41.86%) |
iCTCs>5Δ
75 (58.14%) |
P- value§ |
CA125≤35◇
24 (27.9%) |
CA125>35◇
62 (72.1%) |
P- value§ |
|
|---|---|---|---|---|---|---|---|
| Age (mean ± SD) | 55.86 ± 11.24 |
59.94 ± 12.77 |
0.051 | 57.65 ± 12.00 |
57.80 ± 12.35 |
0.8404 | |
| Stage* | Benign (n=41) | 39(72.22%) | 2(2.67%) | <0.0001 | 16(66.67%) | 5(8.06%) | <0.0001 |
| I (n=13) | 8(14.81%) | 5(6.67%) | 3(12.5%) | 6(9.68%) | |||
| II (n=4) | 2(3.7%) | 2(2.67%) | 1(4.17%) | 2(3.23%) | |||
| III (n=50) | 4(7.41%) | 46(61.33%) | 3(12.5%) | 35(56.45%) | |||
| IV (n=21) | 1(1.85%) | 20(26.67%) | 1(4.17%) | 14(22.58%) | |||
| Grade* | 1 (n=6) | 2(18.18%) | 4(6.35%) | 0.2514 | 3(50%) | 1(2.04%) | 0.0033 |
| 2 (n=3) | 1(9.09%) | 2(3.17%) | 0(0%) | 3(6.12%) | |||
| 3 (n=65) | 8(72.73%) | 57(90.48%) | 3(50%) | 45(91.84%) | |||
| Histology* | Serous (n=44) | 6(40%) | 38(52.05%) | 0.1317 | 5(62.5%) | 28(49.12%) | 0.4943 |
| papillary serous (n=17) |
3(20%) | 14(19.18%) | 0(0%) | 12(21.05%) | |||
| endometrioid (n=2) | 1(6.67%) | 1(1.37%) | 0(0%) | 1(1.75%) | |||
| clear cell (n=6) | 3(20%) | 3(4.11%) | 0(0%) | 3(5.26%) | |||
| Other+Mix (n=19) | 2(13.33%) | 17(23.29%) | 3(37.5%) | 13(22.81%) | |||
| Cancer type* | Ovary (n=76) | 13(86.67%) | 63(86.3%) | 0.6746 | 6(75%) | 48(84.21%) | 0.7233 |
| Primary Peritoneal (n=9) |
1(6.67%) | 8(10.96%) | 1(12.5%) | 7(12.28%) | |||
| Fallopian Tube (n=3) |
1(6.67%) | 2(2.74%) | 1(12.5%) | 2(3.51%) | |||
| Debulking* | Optimal (n=69) | 13(100%) | 56(86.15%) | 0.3424 | 6(100%) | 47(87.04%) | 1.000 |
| Suboptimal (n=9) | 0(0%) | 9(13.85%) | 0(0%) | 7(12.96%) | |||
| Platinum sensitivity* |
Sensitive (n=39) | 10(83.33%) | 29(59.18%) | 0.1821 | 3(75%) | 31(72.09%) | 1.000 |
| Resistant (n=22) | 2(16.67%) | 20(40.82%) | 1(25%) | 12(27.91%) | |||
| Subsequent recurrence (as of 12/31/2012) (n=34) |
4 | 30 | <0.0001 | 5 | 25 | 0.1300 | |
| Subsequent death (as of 12/31/2012) (n=46) |
5 | 41 | <0.0001 | 1 | 34 | <0.0001 | |
Δ
A baseline of >5 iCTCs/l.0-mL blood in 48 healthy women donors was chosen as the assay sensitivity cutoff (see text for discussion); a baseline of CA125>35 U / mL was chosen as cutoff
◇
All 129 patients in the study group were analyzed for iCTCs; 86 patients of benign and EOC underwent comparison of iCTCs vs serum CA125.
*
Benign samples were not included for these characteristics.
§
P-values were given by Fisher’s exact test for binary variables. Pearson’s Chi-square test for multinomial variables and Wilcoxon rank sum test for continuous variables.